Healthleap, a San Francisco-based clinical AI company, has raised $38 million in combined seed and Series A funding to expand a platform designed to help hospitals identify conditions that may otherwise go undiagnosed. The financing came from Sequoia Capital, First Round Capital, and Hummingbird Ventures, and will support further product development, expansion into additional clinical conditions, and hiring across engineering, sales, customer success, and product. Healthleap says its technology is already used across more than 50 hospitals, including Penn Medicine, Houston Methodist, Cedars-Sinai, and Emory Healthcare.
Funding and Expansion
The company’s platform analyzes patient records on a recurring basis and surfaces individuals who may require additional clinical attention, with the aim of helping care teams intervene earlier. Healthleap currently focuses heavily on malnutrition screening, but plans to extend its technology to areas including congestive heart failure, pressure ulcers, hospital-acquired infections, and other conditions. The new capital is intended to accelerate that broader clinical expansion while strengthening the teams needed to deploy and support the technology across more health systems.
Addressing Missed Diagnoses
Healthleap is targeting a persistent challenge for hospitals, where understaffed teams and manual screening processes can make it difficult to identify high-risk patients consistently. The company points to malnutrition as an example, noting that many hospitals still rely on limited admission-time screening even though vulnerable patients may be unable to answer questions accurately. Healthleap cites research indicating that a significant share of hospitalized patients may be at risk of malnutrition while only a comparatively small proportion receive a formal diagnosis.
How the Platform Works
The Healthleap system connects with electronic health record workflows and continuously reviews information such as clinical notes, laboratory results, vital signs, orders, and problem lists. It then generates risk signals intended to help clinicians prioritize patients who may need assessment or treatment, rather than relying solely on one-time screening at admission. According to the company, this approach enables hospitals to screen patients more frequently and with greater precision while integrating the results into existing clinical processes.
Hospital and Financial Impact
Healthleap says hospitals using its technology have reported improvements in case identification as well as financial benefits linked to reimbursement and shorter lengths of stay. One Penn Medicine hospital, according to the company, observed an estimated $23.8 million in annual financial impact from incremental reimbursement and reduced length of stay, while another cited example involved a 39% increase in identified and treated malnutrition cases. The company also says severe malnutrition diagnoses can support significant reimbursement for hospitals when patients receive appropriate documented care.
Founders and Company Development
Healthleap was founded in 2022 by siblings Josiah Meyer and Jemima Meyer, who built the company around the idea of using clinical data to identify patients earlier in the course of care. Jemima Meyer’s experience as a clinician helped shape the platform’s focus on tools that can support faster recognition and treatment, while Josiah Meyer serves as chief executive. The company describes its broader goal as building preventive clinical systems that help hospitals improve outcomes while reducing the costs associated with missed or delayed diagnoses.
With $38 million in new funding, Healthleap is positioning itself to expand beyond malnutrition screening and apply its clinical AI infrastructure to a wider range of hospital conditions. The company enters that next phase with deployments across dozens of hospitals and backing from several prominent venture investors, but its growth will depend on demonstrating that its tools can deliver consistent clinical value across different health systems and use cases. As hospitals continue looking for ways to manage staffing pressure, improve detection, and reduce avoidable costs, Healthleap is betting that automated screening can become a more central layer in clinical workflows.